Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anadys Pharmaceuticals, Inc.

http://www.anadyspharma.com/

Latest From Anadys Pharmaceuticals, Inc.

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Market Intelligence Innovation

Gilead Touts Catalyst-Rich 2024 Amid Sales Slump

The drug maker pointed to a variety of key trial readouts over the course of the year, including the pivotal study of its long-acting HIV PrEP injectable and Phase III updates for Trodelvy.

Sales & Earnings Companies

Encouraging Phase III Data For Blenrep But GSK Remains Cautious On Market Return

Data may prove too little too late for the antibody drug conjugate, as GSK takes a cautious stance over future commercial viability.

Commercial Clinical Trials

Focus On Execution Pays Off Across Bristol’s New Product Portfolio

BMS reiterated its 2024 focus on execution across its portfolio and R&D pipeline as it works through upcoming losses of exclusivity, and its fourth quarter revenues reflected year-end efforts to drive sales.

Launches Growth
See All

Company Information

UsernamePublicRestriction

Register